Based on the strategies above, we successfully generated a novel aptamer AptW2-1-39-PEG with high affinity (KD 7.86 nM) targeting CTGF, which was characterized thoroughly for its satisfactory sensitivity (minimum protein binding concentration, 2 ng), specificity (negative binding to other biomarkers of RA), and stability (viability-maintaining duration in human serum, 48 h) properties using various biochemical and biophysical assays. Here, CCN2 is linked to rheumatoid arthritis.